000 01213 a2200349 4500
005 20250517134656.0
264 0 _c20181029
008 201810s 0 0 eng d
022 _a2168-6084
024 7 _a10.1001/jamadermatol.2016.5059
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMuggli, David
245 0 0 _aSecukinumab for Acrodermatitis Continua of Hallopeau.
_h[electronic resource]
260 _bJAMA dermatology
_c04 2017
300 _a336-337 p.
_bdigital
500 _aPublication Type: Case Reports; Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAcrodermatitis
_xdiagnosis
650 0 4 _aAged, 80 and over
650 0 4 _aAntibodies, Monoclonal
_xadministration & dosage
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aBiopsy
650 0 4 _aFoot Dermatoses
_xdiagnosis
650 0 4 _aHumans
650 0 4 _aMale
650 0 4 _aSkin
_xpathology
700 1 _aMaul, Julia-Tatjana
700 1 _aAnzengruber, Florian
700 1 _aFopp, Myriam Wyss
700 1 _aNavarini, Alexander A
773 0 _tJAMA dermatology
_gvol. 153
_gno. 4
_gp. 336-337
856 4 0 _uhttps://doi.org/10.1001/jamadermatol.2016.5059
_zAvailable from publisher's website
999 _c26817661
_d26817661